The NHS has turned to US drugs giant Pfizer over its British rival GSK for vaccines against Respiratory Syncytial Virus (RSV), the winter infection known as the “silent killer” of the elderly.
As Dame Emma Walmsley stood up to deliver GSK’s latest set of results last month, she was brimming with confidence. This was “another excellent” period, she said, with sales and profits at the company booming.
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk